New Alzheimer’s drug Q&A

New Alzheimer’s drug Q&A

We still are learning about the new Alzheimer’s drug, Aducanumab (ADUHELM) and its roll out following the FDA’s recent approval. We will continue to update this form as new information becomes available. Dr. Kenneth Pugar discusses new drug here. Who can...
FDA approves first Alzheimer’s drug in years

FDA approves first Alzheimer’s drug in years

DAYTON, OH (DCND) – The Food and Drug Administration has approved the first drug for Alzheimer’s Disease in nearly 20 years. The Biogen drug, Aduhelm (Aducanumab) helps clear a protein linked with Alzheimer’s called beta-amyloid. It’s an...
DCND starts Multiple Sclerosis podcast

DCND starts Multiple Sclerosis podcast

Dayton Center for Neurological Disorders is starting a monthly podcast with the hope of educating patients on Multiple Sclerosis (MS) and its impacts. Every month, a DCND provider will tackle a different topic to help patients manage their disease and live a better...
LabCorp to hold office hours at DCND

LabCorp to hold office hours at DCND

LabCorp will be holding office hours at our Centerville office at 1975 Miamisburg-Centerville Rd. Centerville, OH 45459. Monday-Friday 8:30AM – 12:30PM Why the change? Due to several issues getting lab results back in a timely manner with CompuNet, we have...
COVID-19 vaccine questions answered

COVID-19 vaccine questions answered

We understand that a lot of patients have questions surrounding the COVID-19 vaccine. We are putting together a list of the most common questions our office staff is getting to better help direct you to information to make an informed decision. Do you or will you...
MS Patients & COVID-19

MS Patients & COVID-19

DCND is closely monitoring the spread of COVID-19 and we recognize many of our patients are considered immune compromised. Multiple Sclerosis itself does not increase the risk of contracting COVID but there may be factors associated with your diagnosis that can...